The question this episode answers
How can a vaccine prepare the body to defeat a dangerous infection before that infection has had a chance to cause serious harm?
A clear look at how vaccines train the body to recognize and fight dangerous diseases.
Researched & cited
Every claim is researched from multiple sources and cross-checked before narration. Daycast is made with AI — researched, written, and narrated — and we say so in every episode. Sources below.
- Principles of innate and adaptive immunity - Immunobiology - NCBI Bookshelf
- Innate immune system - Autoimmunity - NCBI Bookshelf
- Innate Immunity - Molecular Biology of the Cell - NCBI Bookshelf
- Innate and adaptive immune responses against picornaviruses and their counteractions: An overview - PMC
- How Infection Works - What You Need to Know About Infectious Disease - NCBI Bookshelf
- Vaccines - PMC
- About Sepsis | Sepsis | CDC
- Measles
- Measles
- Clinical Signs and Symptoms of Influenza | Influenza (Flu) | CDC
- Chapter 1: Principles of Vaccination | Pink Book | CDC
- Explaining How Vaccines Work | Vaccines & Immunizations | CDC
- How do vaccines work?
- The Power of Memory: Fighting Disease With Vaccines and Immunization
- How vaccines work
- Against The Odds:Making a Difference in Global Health
- Overview of the Immune System | NIAID: National Institute of Allergy and Infectious Diseases
- Understanding How COVID-19 Vaccines Work | CDC
- Vaccines and immunization: What is vaccination?
- Immunization - PMC
- The Integrated Consideration of Vaccine Platforms, Adjuvants, and Delivery Routes for Successful Vaccine Development - PMC
- Vaccines: Underlying Principles of Design and Testing - PMC
- Conjugate Vaccines and the Carriage of Haemophilus influenzae Type b - Volume 2, Number 3—July 1996 - Emerging Infectious Diseases journal - CDC
- Understanding Viral Vector COVID-19 Vaccines | CDC
- An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines - PMC
- Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important? - PMC
- U.S. Vaccine Names | Vaccines & Immunizations | CDC
- mRNA COVID-19 Vaccines: An Incredible Feat of Genomic Technology | Blogs | CDC
- WHO Expert Committee on Biological Standardization — Seventy-fourth report
- From legacy to innovation: A comprehensive review of vaccine platforms against viral infections - PMC
- Vaccine Effectiveness | COVID-19 | CDC
- Glossary | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | New England Journal of Medicine
- Vaccines and Related Biological Products Advisory Committee December 10, 2020 Meeting Briefing Document- FDA
- Vaccine efficacy, effectiveness and protection
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | New England Journal of Medicine
- Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025 | MMWR
- Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR
- Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025 | MMWR
- WHO/IVB/10.13
- Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19
- Contraindications and Precautions | Vaccines & Immunizations | CDC
- People with Certain Medical Conditions and COVID-19 Risk Factors | Covid | CDC
- Clinical Questions about Measles | Measles (Rubeola) | CDC
- The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants - PMC
- About Global Measles | Global Measles Vaccination | CDC
- Chapter 7: Measles | Manual for the Surveillance of Vaccine-Preventable Diseases | CDC
- Measles Cases and Outbreaks | Measles (Rubeola) | CDC
- Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024 | MMWR
- Direct and Indirect Effects of Routine Vaccination of Children with 7-Valent Pneumococcal Conjugate Vaccine on Incidence of Invasive Pneumococcal Disease --- United States, 1998--2003
- Chapter 11: Pneumococcal | Manual for the Surveillance of Vaccine-Preventable Diseases | CDC
- Vaccinating Pregnant Patients | Whooping Cough | CDC
- WHOGPV/GEN/95.03 Rev.1
- WHO Library Cataloguing-in-Publication Data
- F) Indirect Protection (Herd Protection)
- A note on variable susceptibility, the herd-immunity threshold and modeling of infectious diseases - PMC
- Benefits of Flu Vaccination | Flu Vaccines Work | CDC
- Interim statement on hybrid immunity and increasing population seroprevalence rates
- Adaptive immunity and SARS-CoV-2
- Vaccine efficacy, effectiveness and protection
- Publication title
- Mucosal immune responses to infection and vaccination in the respiratory tract - PMC
- SARS-CoV-2 Vaccines: The Mucosal Immunity Imperative - PMC
- Prevention of host-to-host transmission by SARS-CoV-2 vaccines - PMC
- Chapter 2: General Best Practice Guidance for Immunization | Pink Book | CDC
- Possible Side Effects from Vaccines | Vaccines & Immunizations | CDC
- Preventing and Managing Adverse Reactions | Vaccines & Immunizations | CDC
- Chapter 4: Vaccine Safety | Pink Book | CDC
- Vaccines and immunization: Vaccine safety
- Tissue-resident memory T cells and lung immunopathology - PMC
How was this episode?
Related episodes
What DNA Does
Technology & ScienceAug 13, 202625 min
